IP Library Granted Patent US 7,081,459
Granted Patent B2
US 7,081,459 · App. 11/122,246 · Granted Jul 25, 2006

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Assignee: Neurocrine Biosciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,081,459
App. No.
11/122,246
Granted
Jul 25, 2006
Kind
B2
Abstract

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein A, R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , R 6 , and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Claims (31)

1. A compound having the following structure:

or a stereoisomer or pharmaceutically acceptable salt thereof,

wherein:

A is N or CR 7 ;

n is 2, 3 or 4;

R 1 and R 2 are the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, —C(R 8 )(═NR 9 ) or —C(NR 10 R 11 )(═NR 9 );

or R 1 and R 2 taken together with the nitrogen atom to which they are attached form a heterocycle or a substituted heterocycle;

R 3a and R 3b are the same or different and, at each occurrence, independently hydrogen, alkyl, substituted alkyl, alkoxy, alkylthio, alkylamino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, —COOR 12 or —CONR 10 R 11 ;

or R 3a and R 3b taken together with the carbon atom to which they are attached form a homocycle, substituted homocycle, heterocycle or substituted heterocycle;

or R 3a and the carbon to which it is attached taken together with R 1 and the nitrogen to which it is attached form a heterocycle or substituted heterocycle;

R 4 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl;

R 5 is hydrogen, alkyl, or substituted alkyl;

R 6 is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

R 7 is hydrogen, alkyl, or substituted alkyl;

R 8 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

R 9 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

R 10 and R 11 are the same or different independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl; and

R 12 is hydrogen, alkyl, or substituted alkyl.

2. The compound of claim 1 wherein R 1 is hydrogen, alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, heterocyclealkyl or substituted heterocyclealkyl.

3. The compound of claim 1 wherein R 4 is arylalkyl, substituted arylalkyl, or heteroarylalkyl.

4. The compound of claim 1 wherein R 6 is aryl, substituted aryl, or heteroaryl.

5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

6. A method for treating a condition selected from the group of endometriosis, breast cancer, prostate cancer and benign prostatic hypertrophy in a subject in need thereof, comprising administering to the subject an effective amount of a compound of claim 1 .

7. The method of claim 6 wherein the condition is endometriosis.

8. The method of claim 6 wherein the condition is breast cancer.

9. The method of claim 6 wherein the condition is prostate cancer.

10. The method of claim 6 wherein the condition is benign prostatic hypertrophy.

11. A method for preventing pregnancy in a subject in need thereof, comprising administering to the subject an effective amount of a compound of claim 1 .

12. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or diluent.

13. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier or diluent.

14. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier or diluent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2019
From: CHEN, CHEN; WU, DONGPEI; GUO, ZHIQIANG; ROWBOTTOM, MARTIN
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 048243/0625 →
CONFIRMATORY LICENSE Recorded Oct 5, 2010
From: NEUROCRINE BIOSCIENCES, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025092/0199 →
Continuity (4)
Continuation 1083209200 · Apr 26, 2004
Continuation 1021197200 · Aug 2, 2002
Provisional Application 6031001900 · Aug 2, 2001
Related Publication 20050272733A1 · Dec 8, 2005